Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InSilico Medicine Cayman TopCo's EBIT per Share for the
three
months ended in Dec. 2025 was $-4.23.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.27.
During the past 3 years, the average EBIT per Share Growth Rate was -76.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for InSilico Medicine Cayman TopCo's EBIT per Share or its related term are showing as below:
ISLMF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -76.5 Med: -76.5 Max: -76.5
Current: -76.5
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of InSilico Medicine Cayman TopCo was -76.50% per year. The lowest was -76.50% per year. And the median was -76.50% per year.
ISLMF's 3-Year EBIT Growth Rate is ranked worse than 97.11% of 2114
companies
in the Software industry
Industry Median: 11.85
vs ISLMF: -76.50
InSilico Medicine Cayman TopCo (OTCPK:ISLMF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
InSilico Medicine Cayman TopCo EBIT per Share Related Terms
InSilico Medicine Cayman TopCo EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.27
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo (ISLMF) has a EBIT per Share of $-4.27 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on InSilico Medicine Cayman TopCo and its competitors. According to the industry distribution chart, InSilico Medicine Cayman TopCo ranks #2053 out of 2114 companies in the Software industry, placing it in the top 97.1%.
Is InSilico Medicine Cayman TopCo's EBIT per Share too high?
InSilico Medicine Cayman TopCo's current EBIT per Share is $-4.27. Based on the distribution chart, InSilico Medicine Cayman TopCo ranks #2053 out of 2114 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's EBIT per Share compare to ?
According to the Software industry distribution chart, InSilico Medicine Cayman TopCo ranks #2053 out of 2114 companies for EBIT per Share. This places InSilico Medicine Cayman TopCo in the lower half of its industry. The industry median EBIT per Share is 11.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Software company?
The median EBIT per Share among Software companies is 11.85, based on 2,114 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on InSilico Medicine Cayman TopCo and its competitors. For the Software industry, the median EBIT per Share is 11.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InSilico Medicine Cayman TopCo's current EBIT per Share is $-4.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (ISLMF) has a current EBIT per Share of $-4.27. The current EBIT per Share is $-4.27. InSilico Medicine Cayman TopCo's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (ISLMF), the current EBIT per Share is $-4.27 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
13GF Score
Get the complete analysis for ISLMF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISLMF has been successfully added to your 
